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ABSTRACT 
 
Medical biotechnology is used by two main types of companies. First, large companies, such as large 
pharmaceutical companies (“big pharma”), which draw on a long history in the given field and 
develop into more and more innovative biotechnology users. Second, modern biotechnological 
companies, from which the above mentioned large companies purchase knowledge, projects or 
services. In terms of developing and spreading technology, small biotech companies often play an 
important mediating role between science and industry. They provide technology-platforms, 
knowledge, services for larger companies, such as international pharmaceutical companies or 
enterprises in the food processing industry. The volume and complexity of biotech and 
pharmaceutical projects grew in relation to the amount of available information and acquired 
knowledge. This placed further emphasis on cooperations, and sharing of costs and risk. Due to the 
risk associated with biotechnology, the complexity of and adherence to rules and the amount of 
funds, companies were forced to cooperate. First, the necessary monetary tools are available only at 
the largest companies. Second, the necessary competencies are often missing, because no matter 
whether a smaller company is market leader in R+D, when it still does not have the necessary 
experience for production, not even the knowledge for clinical testing. As a consequence, cooperation 
is necessary to fill these gaps. 
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INTRODUCTION 
 
Biotechnology, just like other new and dynamically growing branches of industry, is 
undergoing very rapid changes. This is a very high risk – high benefit industry, and 
R+D phases often require several hundred millions of dollars. Participants seek to 
minimize and share uncertainties and risks. A possible solution for this is to 
promote cooperations. Thus, on one hand, biotech companies with specific 
knowledge become importers of knowledge for big pharmaceutical companies, 
while on the other hand, they receive share of the great companies’ profit. Unique 
features and advantages of these cooperations may prevail, which can lead to 
further specifications. 
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THE WAY BIOTECH AND PHARMACEUTICAL COMPANIES 
DEPEND ON EACH OTHER 
 
Medical biotechnology is used by two main types of companies. First, large 
companies, such as large pharmaceutical companies (“big pharma”), which draw on 
a long history in the given field and develop into more and more innovative 
biotechnology users. Second, modern biotechnological companies, from which the 
above mentioned large companies purchase knowledge, projects or services. 
As for revenue and the number of employees, it is mainly the large companies 
that control the biotechnology industry. This, however, does not lead to strict 
adherence to traditions and the conservation of power relations. As a matter of 
fact, in terms of knowledge and the number of innovative projects, the mass of 
small biotech companies has the advantage. 
In terms of developing and spreading technology, small biotech companies often 
play an important mediating role between science and industry. They provide 
technology-platforms, knowledge, services for larger companies, such as international 
pharmaceutical companies or enterprises in the food processing industry. Their 
products can be potential pharmaceuticals, new targets, diagnostic kits, or simply 
specific knowledge. Biotech companies use their networks to mediate knowledge 
between the scientific sphere and their own customers. These networks endeavour to 
find cutting edge research opportunities which are fit for commercial use. 
Many biotech companies were founded in the 70s and 80s. They sought to 
become completely vertical companies, encompassing everything from R+D to 
production and sales. They focused their strategies on developing pharmaceuticals 
for previously non-curable or hard curable, but relatively common diseases. 
Examples for them are Genentech and Amgen, which were successful enough to 
become independent, that is, to encompass all the fields from research to sales. 
These companies brought new trends in their innovation strategies. Previously they 
used only closed innovation. The previously stated companies took to cooperating 
and used different business models. Accordingly, they developed a different 
organizational structure and a different organizational culture. These changed their 
position and behaviour towards their competitors. They marketed (sold, licensed) 
some protected technologies, which they themselves had developed, this way they 
helped their competitors to a certain extent, but helped their own markets to form 
at the same time, furthermore, they could spend their revenue on developing new 
technologies. 
At first companies lacked two factors that kept them from reaching their goals: 
the lack of funds and experienced managers. It is precisely these two things, 
however, that are needed (in addition to technology) for a company to grow from a 
spin-off enterprise to a large pharmaceutical company. The classic pharmaceutical 
companies, enjoying their peak at the time, already possessed these resources. Some 
of them purchased biotech companies, while others were not open to 
biotechnology in terms of investment and cooperation (Murray, 2002). 
In the 90s emphasis was shifted to pharma-biotechnology. That time it was less 
problematic to involve cooperating partners and capital, mainly in the USA.  
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The volume and complexity of biotech and pharmaceutical projects grew in relation 
to the amount of available information and acquired knowledge. This placed 
further emphasis on cooperations, and sharing of costs and risk. 
Recently, biotech companies entered the early phases of research, selling their 
products, ideas and results to pharmaceutical producers (Mark and Smith, 2003). 
These companies were small. Therefore they could not even think about producing 
their own product. Selling their knowledge was something they could realize. Many 
of them went bankrupt, were not successful, but there were those that survived this 
early phase. 
Large pharmaceutical companies usually purchase finished molecules, before or 
after the 2nd clinical phase from the small biotech companies. This means that with 
the technological development is already some win-win situation realized this way. 
Big companies reduce their risks, which however still remained considerable, even 
in this phase, but at the same time the cooperation with the smalls allow small 
biotech companies to prosper. New forms, new players were formed. CMO units 
(contracted place of production) for example, CRO organizations (contracted 
research unit), consulting and service companies. In other words the organizations 
share the risk, the same way they share the work and the income. 
Figure 1 shows the risk sharing process (arrows were added by author). By their 
nature, completely new biotechnological projects, aiming at radical innovation, 
originally fall into the “suicide box”. They are characterized by high market and 
technological uncertainty. In a given situation, a small biotech company, since it has 
no other choice, working out the right technology, sells it to the larger 
pharmaceutical company. From the point of views of the big company, the 
technological uncertainty is reduced considerably, since it is purchasing a 
technology that has been proven to work. (The technology is over the proof of the 
concept phase) The market uncertainty remains now to solve, which can be 
assessed and estimated by the purchaser. Another extreme case is when a small 
innovative company tries to become a supplier for one of the large market players. 
Trying to meet its needs, perhaps even relocating closer to the purchaser, is thus 
reducing market uncertainty for both parties. Thus the reason for cooperation is to 
decrease at least one, but preferably both (marked by dashed arrow) uncertainties. 
By sharing the associated risks, the organizations will not be able to reach the small 
innovation level, as this is not the goal of the cooperation. But at least they can 
decrease risk somewhat. 
Due to the risk associated with biotechnology, the complexity of and adherence 
to rules and the amount of funds, companies were forced to cooperate. First, the 
necessary monetary tools are available only at the largest companies. Second, the 
necessary competencies are often missing, because no matter whether a smaller 
company is market leader in R+D, when it still does not have the necessary 
experience for production, not even the knowledge for clinical testing. As a 
consequence, cooperation is necessary to fill these gaps. 
At the same time, the other perspective is sharing the uncertainties. They may 
be technology, market, regulation or competition related. The latter reflects on the 
segments of all the other risks, since the rapid development of China, South Korea 
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and India is clearly visible. The advantage against these new participants can only be 
quality and knowledge, precisely the areas where China and India are developing 
rapidly, while maintaining the seemingly natural price advantage. Europe and the 
USA can only compete with these products if they do not count on price 
advantage, but on therapeutic advantage. That is, they produce a newer, better 
molecule. However, this larger added intellectual value implies larger risks on behalf 
of technology, market and registration. These tendencies are also catalysts of 
cooperation. 
It is precisely these different, yet interrelated risks that make pharmaceutical 
biotechnology complex. Complex processes and instability necessitate cooperation. 
Instabilities are cross-linked, they have effects on each other, they can even 
strengthen or weaken each other. An example for strengthening is the technological 
uncertainty of producing a new molecule, and the following registration and 
legalization processes. 
 
Figure 1 
 
2-dimensional uncertainties 
 
 
Source: Based on Hronszky and Várkonyi, 2006 
 
Necessity of cooperation can be explained from another point of views as well (Figure 
2). Validity period of a patent is 20years from the date of application, which, in case 
of pharmaceuticals can be extended by at most 5years (SPC). The product generally 
appears on the market 13-15years after the patent application. However, with the end 
of the patent period, one must also count with the appearance of generic and 
biosimilar products. As a result of this, there is at most 10, but more often only 5years 
to cover the entire costs of R+D and clinical trials. That is the reason why everyone 
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seeks to minimize R+D time as much as possible. One method could be open 
innovation, which supports cooperation and outsourcing instead of solving 
everything in-house. Since there is no time to localize new skills within the company, 
it is better to entrust R+D tasks to outsiders who are already experts in the given 
field. This method definitely saves time and possibly costs as well. 
 
Figure 2 
 
Typical timeline in biotech: R&D value chain and patent protection  
 
 
 
BIOTECHNOLOGICAL STARTUPS, FEATURES OF THE 
PHARMACEUTICAL SECTOR 
 
Biotechnological companies pursue B2B (business to business) strategy (the smaller 
they are the more they do so). That is, they hand on their products and services to 
other business organizations instead of end users/consumers. As for 
pharmaceutical development, from all the cooperating partners it is only the large 
pharmaceutical company that gets in contact with the B2C (business to consumer) 
model and the consumer. 
For startup biotechnological enterprises, just like for other startup companies in 
the knowledge intensive sector, the existence of the following is crucial: 
- Possessing new technologies, patents 
- Academic or university background 
- Workforce with great expertise in different sectors (professional expertise, e.g. from 
the industry or university, R+D; management and company leadership) 
- Appropriate scientific and business environment. 
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New companies face many obstacles. It is difficult to find proper workforce, their 
employees are often not committed enough – or they cannot make them 
committed enough. Companies have little expertise in their new environment. All 
of their relations are new – with their costumers, their vendors, their partners, etc. 
These companies are small, and they are often unable to survive a performance 
decline, even if it occurs due to an exterior reason. 
Startup companies are threatened by a lot of technological dangers, they often 
take part in the early phase of developments with the highest risk factor, so they 
and their technology have uncertain values. Furthermore, developments often 
require a considerable amount of capital, yet the amount of revenue is uncertain. 
Innovative biotechnological companies have special characteristics. We can 
observe three remarkable features: 
(I) Biotechnological developments are generally based on the appearance of a 
great number of small and medium-sized companies. As a rule, biotechnology is a 
great and turbulent population of innovators, where small companies are the 
engines of science-aided innovation. Large companies rather play a role in 
integrating new results in their products, after they have been developed by small 
companies. 
(II) Biotechnology is a knowledge-intensive sector. The resulting special 
characteristics have two consequences. Start-up companies are near the source of 
the knowledge, e.g. universities, even if they are not university spin-offs. Second, 
founders come from scientific fields, they have a scientific background. 
(III) Strategic cooperations are becoming a central feature in biotechnology. 
These cooperations help companies gain considerable advantage over stand-
alone companies in terms of resources and abilities. The competencies of 
cooperating partners complement each other, which leads to new opportunities, 
e.g. new technologies can be developed, new markets can be captured. Mason 
(McCutchen and Swamidass, 2004) and Calazo explained the advantages as follows: (1) 
the technological gap is filled, market is provided for replenishing production 
capacity; (2) initial cost and risk are reduced; (3) new products can be marketed 
faster; (4) size-efficiency is reached; (5) trade and legal obstacles are easier to 
overcome; (6) extended field of activity; (7) decreasing specific cost. 
In biotechnology small companies use outer R+D capacities (as well). The 
reason for this is the lack of inner resources (money and knowledge). Yet other 
factors also support the idea to rely on outer resources: (1) the management 
endeavours to complete inner resources (2) the environment feels that R+D is too 
risky and difficult, because products and regulation are changing too fast; (3) the 
company seeks to reduce the risk; (4) the company has experience in using outer 
resources; (5) the management have a strong global approach (Atuahene and Gima, 
1999). 
Biotechnology and pharmaceutical companies often cooperated since the time 
they could achieve a “win-win” type (that is, advantageous for both parties) 
cooperation through helping each other. A small company can come in for the 
cooperation in different ways. Of course it cannot invest hundreds of million 
dollars and cannot wait for years for the payback. The small company gets a certain 
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ratio of the revenue of marketing, so its value and prestige is increasing, it can easier 
gain new partners and investors. 
In biotechnology company success requires 3 different competencies: strong 
management, financial resources, good technology. Out of these criteria, strong 
management is the most important one, of course, since they can obtain money and 
control research directions. On the other hand, the available capital and technology 
alone are not enough for the success. Since in biotechnological strategies the 
product's or service's novelty are more important than their prize advantage, 
technology requires a considerable amount of investment, a long time before any 
revenue could be generated. 
 
THE KEY TO SUCCESS: COOPERATION BETWEEN 
BIOTECHNOLOGICAL AND PHARMACEUTICAL COMPANIES 
 
In the 90s organizations differentiated in the sector, platforms (cooperation 
samples) were formed and were often used (author’s and patent royalties, research 
and licence agreements, spontaneous cooperations, formal and informal alliances 
between supplier companies, organizations). Nowadays this phenomenon is getting 
intensified because of the complexity of projects (e.g., human genome), the amount 
of knowledge in life sciences, as well as the complexity of pharmaceutical 
requirements. Today biotech companies’ strategy allows the existence of more and 
more product-orientated enterprises in the medical industry. 
The increasing complexity created paradoxes systematically: a global 
competition emerged, this, however, caused cooperations too. The reason for this 
was that cooperations helped reach the critical mass which ensured success. 
Even these days, biotechnology companies are smaller than traditional 
pharmaceutical companies, but their small size is compensated by them being 
highly specialized and mobile, and reacting faster to tendencies. Their other 
advantage is cooperation, which they are forced to form, because cooperations are 
becoming more and more important. According to today's requirements, the 
development of the increasing number of new molecules and pharmaceuticals 
needs a lot more energy and money as it did a few decades ago. Companies need to 
cooperate since only a few companies can afford to invest 800-1200 M $ in a very 
risky pharmaceutical original project. As a consequence of this, risk and cost 
sharing are necessary. 
The time available is another critical factor. The available 10-15years seem to be 
a long time, but in fact they are not. Clinical trials (3 phases) and the registration 
process last several years each. What is more, one have to act faster than its 
competitors, a few months of delay in the programme can result in another 
company entering the market sooner with a similar active substance. Because of 
special market and industrial property protectional customs and laws the second 
participant entering the market can gain only a small fragment of the turnover –  
which makes it doubtful whether development costs will return. That means 
companies are supposed to enter the market as soon as possible. Accordingly, there 
is a tendency that companies can accelerate the phase of development with the help 
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of knowledge obtained from other organizations rather than using their own 
research results, since pharmaceutical companies purchase already successful, 
immediately available concepts. That is, time limit also necessitates the preference 
of knowledge-brokering and the cooperation of organizations instead of 
strengthening in-house research potentials. 
As for finances, cooperations are controlled and influenced by the large 
pharmaceutical company, even though it only takes part in the real work after Phase 
2, or Phase 3. As a result of this, the large pharmaceutical company also becomes 
dependent on the small ones, which provide technology and knowledge, because it 
builds upon them while investing in markets and production potential. It is more 
economical for it to spend a part of its budget on supporting small companies and 
cooperations than to finance broad R+D. Accordingly, a power imbalance of 
participants is characteristic of biotechnological cooperations. 
Today cooperation is a feature of not only biotechnological companies, but 
most pharmaceutical companies are also forced to form strategic cooperations. 
Small pharmaceutical and biotechnnology companies can achieve an impressive 
result only when they cooperate and share labour to a necessary extent. 
These days the visible tendency is for certain biotechnology companies to 
establish long lasting strategic cooperations with certain pharmaceutical companies. 
That means the biotech company develops its portfolio, its knowledge importers in 
order that its products meet the requirements of the large company comprising its 
market. In certain cases topics and ideas come from the pharmaceutical company 
itself. Accordingly, knowledge importers are becoming more and more specialized. 
Of course these interrelations do not mean exclusivity. New companies and results 
are emerging all the time, new interactions can be formed alongside these 
interrelations. The reasons for interconnections are the important changes in 
knowledge-generation which dynamically influences this branch of industry and its 
specific isntitutes. 
During the struggle for survival and growth, formal and informal cooperations, 
groups of strategy and interest are formed. One of the most importants groups are 
clusters. 
The driving forces of biotechnology and the related modern pharmaceutical 
industry are innovation, the flow of knowledge, the appearance of new ideas and 
technologies in the industry. 
In the sector, several practically realizable solutions were born for knowledge 
flow which innovation required and for cooperations between organizations. Their 
common features are that they bring academic and industrial spheres, as well as 
their needs together; they make new ideas and knowledge obtained in the academic 
sphere to be industrially usable. It is also of crucial importance to reach the “critical 
mass” necessary for the realization, in terms of involving technology – capacity, 
equipment, workforce, suppliers, background industry, infrastructure- as well as 
involving capital necessary for technology operation.  
With cooperations and labour sharing costs and risks are also shared 
automatically. Since pharmaceutical companies prefer to find “knowledge 
importers” with the greatest knowledge and expertise in a certain field, they 
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probably won't need to develop a complete in-house knowledge-base, which results 
in reduced cost and time requirements. Successful projects, industrially realizable 
basic research results are chosen, cooperations are based upon them. Consequently, 
projects cost less in general, because a relatively less amount of money is needed to 
be invested to decide which research result can be utilized at the industrial level. 
That is, there is no need to develop in-house capacities to obtain research results, 
and, on the other hand, small companies and academic institutes cannot afford to 
invest considerable amounts of money in projects. In several cases, projects were 
marketed already after the proof of concept phase, but cooperation cost much less 
until that point. 
At biotechnological companies innovation have special features which have 
been paid great attention to for the last years: 
(1) Just like in every new branch of industry, small companies are typical to exist, 
for which cooperations are beneficial. A further similarity to information 
technology and telecommunication is that the great and stabile companies are 
present rather as key partners and costumers. Cluster organizations often 
depend on them financially, and they also determine strategic business 
directions. This phenomenon is emphasized in biotechnology as well: large 
pharmaceutical companies often establish start-up organizations and contact 
smaller companies, take part in the pharmaceutical production (generally around 
the Phase 2 of clinical research), whereas small biotechnology companies take 
projects from proof of the concept to the Phase 1 of clinical research. A 
significant prerequisite of biotech sector growth is the exponentially increasing 
number of small and medium-sized companies in the sector. The sector of 
biotechnology is often described as the great and turbulent population of 
innovators. Small and medium-sized enterprises represent the power in the 
innovation environment, whereas large companies play a role in integrating new 
developments in their products, after being developed by small and medium-
sized enterprises. 
(2) Biotech is a knowledge-intensive sector. This has two consequences. First, small 
and medium-sized enterprises are near the source of knowledge, even if they are 
not spin-off companies. Second, company founders have mainly a scientific 
background – with all its advantages and disadvantages. 
 
SUMMARY 
 
I presented that in the “high risk – high benefit” biotechnology industry 
participants seek to minimize and share uncertainties and risks. A practical, well 
functioning solution is forming cooperations, groups of interest, networks and 
strategic relations. As a result, biotechnology companies with a specific knowledge 
become knowledge importers for large pharmaceutical companies, on the other 
hand, they gain share of the large companies' profit. Unique features and 
advantages of these cooperations may prevail, which can lead to further 
specifications. 
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